Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
نویسندگان
چکیده
منابع مشابه
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.
BACKGROUND Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the second-line treatment setting. However, given the variety of available targeted therapies for mRCC, ap...
متن کاملAxitinib in Metastatic Renal Cell Carcinoma
Targeted agents have revolutionized the management of metastatic renal cell carcinoma (RCC). Axitinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been an important addition to currently available therapies for advanced RCC. Its ability to inhibit VEGFRs at nanomolar concentrations distinguishes it as a potent tyrosine kinase inhibitor, with increased selectivity fo...
متن کاملAxitinib: Newly Approved for Renal Cell Carcinoma
4503 (Rini et al.) from the 2012 ASCO annual meeting, as well as information on specialty pharmacies and patient assistance. SEE PAGE XXX SEE PAGE 298 erythrodysesthesia (hand-foot syndrome), but this was in a heavily pretreated population. The question of whether these side effects will remain as pronounced in a first-line setting is still unanswered. Of equal importance is whether or not the ...
متن کاملEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit. Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation confirmed in Phase II trials. The trial of comparative effectivess of axitinib versus sorafenib in advanced re...
متن کاملAxitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptors (VEGFRs). Axitinib is an oral second-generation TKI and a potent VEGFR inhibitor with a half maximal inhibitory concentration for the VEGF family receptors 10-fold lower than other TKIs. Axitinib activity in ren...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Nephrology and Renovascular Disease
سال: 2016
ISSN: 1178-7058
DOI: 10.2147/ijnrd.s83874